Targeted Transport of 125I-Labeled Antibody to GFAP and AMVB1 in an Experimental Rat Model of C6 Glioma
- 4 September 2008
- journal article
- Published by Springer Science and Business Media LLC in Journal of Neuroimmune Pharmacology
- Vol. 4 (1), 28-34
- https://doi.org/10.1007/s11481-008-9123-5
Abstract
Glioblastoma is the most common high-grade glioma characterized by strikingly poor therapeutic outcome with survival time of about a year. This makes a search for new therapeutic approaches to glioblastoma treatment an area of great clinical importance. The present study aims to explore the potential of targeted delivery of 125I-radiolabeled antibodies, specific to glial fibrillary acidic protein (GFAP) and AMVB1 (antigen of abluminal membrane of endotheliocytes predominantly expressed in glioblastoma microvessels) as a strategy for in vivo tumor targeting. Rat C6 glioma model was used to test this hypothesis. Tumor bearing animals, injected with radiolabeled monoclonal antibodies to GFAP or AMVB1, were compared to control group, which received nonspecific mouse IgG. Radioactivity of blood, brain hemispheres, and some other tissues was measured 6, 24, 48, 72, and 96 h posttreatment. Our results demonstrate accumulation of both types of antibodies in tumors. Concentrations of both antibodies were significantly increased in tumor-bearing hemisphere compared to intact hemisphere. Antibodies to GFAP specifically accumulated in brain and bound tumor tissue with the high affinity. In contrast, increased accumulation of anti-AMVB1 antibody was detected in antigen-expressing organs, such as spleen and kidney. Based on results presented, we propose that the monoclonal antibodies to GFAP can be used as vectors for the delivery of diagnostic and pharmacological agents to high-grade gliomas. Development of this strategy would open new clinical perspectives for glioblastoma diagnostics and therapy.Keywords
This publication has 21 references indexed in Scilit:
- A targeted transport of 125I-labeled monoclonal antibodies to target proteins in experimental glioma focus.Doklady Biochemistry and Biophysics, 2008
- Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6Journal of Nuclear Medicine, 2007
- Modeling and immunohistochemical analysis of C6 glioma In VivoBulletin of Experimental Biology and Medicine, 2007
- Insulin-like growth factor type I biology and targeting in malignant gliomasNeuroscience, 2007
- Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid TumorsClinical Cancer Research, 2006
- Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.2005
- Relationship between S100β and GFAP expression in astrocytes during infarction and glial scar formation after mild transient ischemiaBrain Research, 2004
- Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasionCell and tissue research, 2002
- Differential expression of connexin43 in foetal, adult and tumour-associated human brain endothelial cells.Journal of Molecular Histology, 2002
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trialInternational Journal of Radiation Oncology*Biology*Physics, 1992